Nice. Great that she responded, and interesting response, the 'or after a study participant completes the study' part gets you thinking.
Not knowing how you asked the initial email, one could speculate they are getting a few emails from patients/physicians hearing about 434 and asking to be considered, or wanting to continue after their 12 months trial, but they can't for whatever reason (maybe low funds or tablets) and this is the standard response they are giving?
That would be really sad if these patients want back on but can't, but at same time would be a good sign for perceived effectiveness of the drug. Again, just my own speculation, we won't know until Jan, but interesting to think about.
Cheers
ATH Price at posting:
0.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)